Condition: Pancreatic Ductal Adenocarcinoma (PDAC) · Sponsor: BioNTech SE
This study will enroll adults with confirmed metastatic pancreatic ductal adenocarcinoma (PDAC, systemic PDAC treatment naïve), Eastern Cooperative Oncology Group performance status (ECOG PS) 0-1, and adequate organ function. Participants will receive pumitamig (also known as BNT327, BMS-986545, or PM8002) in combination with chemotherapy.
This description comes directly from the study's public registry record.
BioNTech clinical trials patient information · +49 6131 9084 · patients@biontech.de
Always discuss trial participation with your own doctor first.
| Flinder's Medical Centre | Bedford Park, Australia | Not Yet Recruiting |
| Pindara Private Hospital | Benowa, Australia | Not Yet Recruiting |
| Peninsula & South Eastern Haematology and Oncology Group | Frankston, Australia | Recruiting |
| The Alfred Hospital | Melbourne, Australia | Not Yet Recruiting |
| St Vincent's Hospital | Melbourne, Australia | Not Yet Recruiting |
| One Clinical Research | Mount Pleasant, Australia | Not Yet Recruiting |
| GenesisCare | Saint Leonards, Australia | Recruiting |
| Sunshine Coast Private Hospital | Sunshine Coast, Australia | Not Yet Recruiting |
| Westmead Hospital | Sydney, Australia | Not Yet Recruiting |
| Tsinghua Changgung Hospital | Beijing, China | Recruiting |
| Jilin Cancer Hospital | Changchun, China | Not Yet Recruiting |
| Sichuan Cancer Hospital | Chengdu, China | Recruiting |
+ 12 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07255404